2005 and
beyond
The feared adversity in the form of the new patents regime
can be expected to goad domestic firms into better financial
discipline and innovative marketing methods, says Narendran
Nair C N
Runaway
strategy would only harm Indian interest
Nod for concurrent phase I trials would be instrumental
in moulding a positive global perception of India rather
than the business prospects, says Jayashree Padmini
Editorial From
Chaos to Order
Express Pharma Pulse completes nine years this month
and enters the tenth. We have come a long way since
1994 when EPP began covering news, views and features
in major functional areas of the pharmaceutical and
allied industry.
Data
bank — The treasure island
Customer Relations Management will be an exercise in futility
if we do not have the data bank of the supportive customers
in the first place, says Ujjal Banerjee
Spurious
drugs - A blot on India
Support from public in general and NGOs in particular
would go a long way in posing a deterrence to the fake
dealers, suggests Harinder S Sikka
Pharma allied:
Core competence holds the key
Core competence will play an important role in determining
the future of many Indian pharmaceutical allied companies
in the post product-patent regime, says Balakrishnan Nair
APIDC VCL’s
biotechnology fund gets fresh commitments from banks
The Rs 150-crore Biotechnology Venture Fund being developed
by APIDC Venture Capital (APIDC VCL) has received fresh
commitments for Rs 10 crore from Bank of Baroda (BoB)
and Rs 5 crore from Punjab National Bank (PNB) taking
the total to Rs 56 crore.
